Advertisement

Topics

Poxel SAS Company Profile

03:21 EST 18th February 2019 | BioPortfolio

Poxel is a new RIPCO that aims to advance promising assets for cardio-metabolic diseases from Research to Phase 2 Clinical Proof of Concept, before out licensing projects to pharmaceutical companies. Poxel will further develop its portfolio by considering all opportunities corresponding to its core domain of competencies.


News Articles [21 Associated News Articles listed on BioPortfolio]

Poxel licenses NASH project from DeuteRx

DeuteRx LLC granted Poxel SA exclusive global rights to DRX065, a Phase I candidate that Poxel intends to develop for nonalcoholic steatohepatitis (NASH).

Poxel initiates second part of PXL065 study to treat NASH

Poxel has initiated the second part of the Phase Ia study of PXL065, which is being developed for the treatment...Read More... The post Poxel initiates second part of PXL065 study to treat NASH appear...

Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan

French biopharmaceutical firm Poxel has concluded patient enrolment in the Phase III TIMES 2 clinical trial of its drug candidate...Read More... The post Poxel closes enrolment in TIMES 2 trial of Ime...

Poxel Adds To NASH Pipeline With Novel Single-Isomer Pioglitazone

Some ground-breaking chemistry has been used to produce a single isomer of pioglitazone, which has been acquired by France's Poxel...   

Deals this week: Biohaven Therapeutics, POXEL, Ossianix

Biohaven Therapeutics has signed a licensing agreement with AstraZeneca for a new drug candidate, AZD3241, targeting a rare neurodegenerative disease....Read More... The post Deals this week: Biohaven...

Poxel begins part 2 of phase 1a study for NASH treatment PXL065

This second part of the Phase 1a study will enroll six healthy subjects per group, with a primary objective to assess safety and tolerability and a secondary objective The post Poxel begins part 2 of...

Poxel Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference

POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes ...

Poxel in €506m diabetes deal with Roivant Sciences

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Safety, Tolerability and PK of PXL770 in Healthy Male Subjects

PXL770 is a direct activator of 5' adenosine monophosphate-activated protein kinase (AMPK) being developed by Poxel S.A. for the treatment of type 2 diabetes mellitus (T2DM). In Part A of ...

Companies [2 Associated Companies listed on BioPortfolio]

Poxel SAS

Poxel is a new RIPCO that aims to advance promising assets for cardio-metabolic diseases from Research to Phase 2 Clinical Proof of Concept, before out licensing projects to pharmaceutical compani...

POXEL S.A.

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alco...

More Information about "Poxel SAS" on BioPortfolio

We have published hundreds of Poxel SAS news stories on BioPortfolio along with dozens of Poxel SAS Clinical Trials and PubMed Articles about Poxel SAS for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Poxel SAS Companies in our database. You can also find out about relevant Poxel SAS Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record